Endometrial Cancer (EC) is still a challenge for gynecological oncologists because the
treatment of the advanced disease remains an unmet need for patients. The Cancer …

Abstract Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease,
accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last …

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …

Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …

Abstract Background PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant
progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus …

Background According to current guidelines, endocrine therapy (ET) is recommended as
first-line treatment of luminal-like metastatic breast cancer (MBC), whereas chemotherapy …

Randomized clinical trials are considered the milestones of clinical research in oncology,
and guided the development and approval of new compounds so far. In the last few years …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Abstract Introduction Randomised controlled trials (RCTs) are usually considered the
highest level of evidence for clinical practice. Patients assigned to control arm in RCTs …

Purpose: The optimal application of maintenance PARP inhibitor therapy for ovarian cancer
requires accessible, robust, and rapid testing of homologous recombination deficiency …